ArticleVaccine2025
Rotasiil vaccine effectiveness against rotavirus-associated hospitalizations in the Democratic Republic of the Congo: comparison of multivariate logistic regression and inverse probability treatment weighting methods in a test-negative design.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundMultinational rotavirus vaccines (Rotarix and RotaTeq) are 43 %-65 % effective in preventing hospitalizations due to rotavirus disease in African countries. The Rotasiil vaccine (Serum Institute of India) offers a potentially cost-effective option but lacks vaccine effectiveness (VE) estimates in African settings. We estimated Rotasiil VE against rotavirus hospitalizations in the Democratic Republic of Congo (DRC) using unconditional multivariate logistic regression and inverse probability of treatment weighting (IPTW) to adjust confounding.
methodsWe examined sentinel surveillance data from two hospitals in Kinshasa (January 1, 2020 to December 31, 2023) for children aged ≤59 months who sought care for acute diarrhea. We used a test-negative case-control design and calculated VE as [1 - adjusted odds ratio (OR) × 100] using unconditional multivariate logistic regression. We compared two approaches to adjust the OR for confounding. First, the OR was adjusted by including the covariates in the model. Second, the OR was adjusted using stabilized IPTW.
resultsIn total, 310 children aged 6 to 30 months were included in the full rotavirus vaccine dose analysis, of which 118 (38 %) were rotavirus positive. The median age was 10 months (range: 8-14), and the proportion of fully vaccinated children was 87 %. The VE measured between fully vaccinated versus unvaccinated children was 60 % (95 % CI: 20-80) by multivariate logistic regression and 79 % (95 % CI: 71-85) by IPTW.
conclusionRotasiil vaccination under conditions of routine use effectively reduces rotavirus-associated diarrhea hospitalizations among children, supporting the ongoing use of rotavirus vaccine. The IPTW VE estimate was more precise than multivariate logistic regression but the confidence intervals overlapped, suggesting that the resulting VE estimates are not statistically different and the methods are complementary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.